SCHEMBL1467702

SCHEMBL1467702

Fc1ccnc2[nH]ccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 5/20 0.61
PRKCI P41743 4/20 0.59
AXL P30530 1/20 0.59
AURKB Q96GD4 3/20 0.52
IKBKB O14920 3/20 0.52
CHUK O15111 3/20 0.52
IGF1R P08069 2/20 0.52
DYRK1B Q9Y463 2/20 0.52
DAPK3 O43293 1/20 0.52
JAK2 O60674 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
PAK4 O96013 1/20 0.52
CSF1R P07333 1/20 0.52
RET P07949 1/20 0.52
FGFR1 P11362 1/20 0.52
PRKACA P17612 1/20 0.52
FLT1 P17948 1/20 0.52
LTK P29376 1/20 0.52
GRK5 P34947 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29605623 1.00 NUDT1 (0.61) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL2240671 0.77 AURKB (0.71) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL4791546 0.76 NUDT1 (0.71) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL12127219 0.76 NUDT1 (0.62) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL858771 0.74 PRKCI (0.59) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL3339974 0.74 PRKCI (0.59) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL99690 0.74 PRKCI (1.00) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL91443 0.74 PRKCI (0.59) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL21062776 0.74 PRKCI (0.59) NUDT1PRKCIAXLAURKBIKBKB
SCHEMBL1176829 0.74 PRKCI (0.59) NUDT1PRKCIAXLAURKBIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116554170-A Preparation method of 4-fluoro-7-azaindole 上海大学 2023-08-08 CN claimed
US-20250361233-A1 Compounds For Activating Serotonin Receptor Psylo Pty Ltd (AU) 2025-11-27 US disclosed
US-12415804-B2 Compounds for activating a serotonin receptor Psylo Pty Ltd (AU) 2025-09-16 US disclosed
US-20250206739-A1 Compounds Psylo Pty Ltd (AU) 2025-06-26 US disclosed
US-20250163044-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-05-22 US disclosed
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS RIBOSCIENCE LLC 2025-02-06 US disclosed
EP-4452979-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 EP disclosed
US-20240327400-A1 COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-10-03 US disclosed
US-12029744-B2 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors RIBOSCIENCE LLC (US) 2024-07-09 US disclosed
CN-115215861-B Aromatic heterocycle substituted alkyne compound and preparation method and application thereof 上海翊石医药科技有限公司 2024-03-15 CN disclosed
EP-1756108-A2 AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2007-02-28 EP disclosed
US-20060058304-A1 Azaindole kinase inhibitors BHIDE RAJEEV S 2006-03-16 US disclosed
US-20060003968-A1 Azaindoles useful as inhibitors of rock and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2006-01-05 US disclosed
US-6969717-B2 Azaindole kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-29 US disclosed
WO-2005103050-A2 AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-11-03 WO disclosed
CN-1681818-A Azaindole kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2005-10-12 CN disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed
EP-1539763-A1 AZAINDOLE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2005-06-15 EP disclosed
US-20040063707-A1 Azaindole kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-04-01 US disclosed
WO-2004009601-A1 AZAINDOLE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206739-A1 Compounds NLN, SLC18A2, PYGB NUDT1 1111/4885PRKCI 3462/4885AXL 4487/4885
US-12415804-B2 Compounds for activating a serotonin receptor HTR2C, HTR6, HTR2A NUDT1 1560/4885PRKCI 2697/4885AXL 2597/4885
US-20250361233-A1 Compounds For Activating Serotonin Receptor HTR2C, HTR2A, HTR6 NUDT1 1712/4885PRKCI 2973/4885AXL 2342/4885
US-20060003968-A1 Azaindoles useful as inhibitors of rock and other protein kinases ROCK2, ROCK1, TNK2 NUDT1 2039/4885PRKCI 37/4885AXL 2432/4885
US-20250041319-A1 BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS ENPP1, ENPP3, SMPD1 NUDT1 110/4885PRKCI 839/4885AXL 4496/4885
US-20040063707-A1 Azaindole kinase inhibitors FGFR1, FGFR2, FLT1 NUDT1 2289/4885PRKCI 757/4885AXL 103/4885
US-12029744-B2 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors ENPP1, ENPP3, SMPD1 NUDT1 103/4885PRKCI 924/4885AXL 4484/4885
US-20250163044-A1 COMPOUNDS NLN, SLC18A2, PYGB NUDT1 1111/4885PRKCI 3462/4885AXL 4487/4885
US-20060058304-A1 Azaindole kinase inhibitors FGFR1, FGFR2, FLT1 NUDT1 2092/4885PRKCI 754/4885AXL 82/4885
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 NUDT1 2299/4885PRKCI 24/4885AXL 1103/4885
US-20240327400-A1 COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH PC, FH, PDK1 NUDT1 2743/4885PRKCI 1258/4885AXL 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.